What we do, we do best: Clinical Research and Development in Osteoarthritis

NBCD is the leading CRO in the OA field, hence: The OA CRO. We are experts in strategic drug development and clinical operations within osteoarthritis. We are highly specialized in protocol development with focus on placebo response mitigation and optimizing the patient population without jeopardizing the operational feasibility of the clinical project. We frequently present our science and share our experience with the scientific community at the most important international scientific conferences, including OARSI, EULAR, and ACR.

NBCD has acquired more than 30 years' extensive experience with clinical trials in rheumatology and musculoskeletal indications. Furthermore, with our legacy from Nordic Bioscience,  our experience in biomarker development allows us to help provide a faster and smarter detection of signals of clinical viability of future treatment options.

We are a science-driven company and engage actively in any phase of drug development; scientifically, operationally, and financially. Each year, we publish several articles in well-respected peer-reviewed journals.